PARP1 and cancer: We uncover DDX11 as a potential target in tumors, including BRCA1/2-mutated cancers that acquired chemotherapeutic resistance, and pinpoint DDX11 mutations/loss as a useful biomarker of responsiveness to platinum drugs, PARP inhibitors, and ATRi.